Posted inGenetics
Turning the Patent Cliff into a Bioplant Opportunity
The 2030 patent cliff may either decimate revenue streams or provide an opportunity for innovation that can transform the biopharmaceutical…
Posted inGenetics
Top 10 U.S. Biopharma Clusters 2026
Some of the forces that shape biopharma cluster development are constants year after year, such as the emergence of startups…
Posted inGenetics
Pharma’s Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset
Erik Terjesen Managing Director Silicon Foundry, a Kearney Company Clinical development has become the most resource-intensive stage of drug innovation.…
Posted inGenetics
Targeted Protein Degradation Broadens Its Scope
Like any complex system, the cell depends on a tightly regulated quality control network to maintain order and prevent the…
Posted inGenetics
Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead
In April 2025, the U.S. Food and Drug Administration (FDA) released a strategic roadmap to make animal testing the exception…
Posted inGenetics
State of the Diagnostic Industry: Recombinants on the Rise
Discovery of a fragile foundation Four years ago in GEN, Scripps Laboratories predicted that the clinical diagnostic industry was on…
Posted inGenetics
Next Generation Biopharma Innovation
Researchers are digging deeper into biology’s complexity. In preclinical research, the traditional in vivo models are simply not enough to…
Posted inGenetics
The Confidence Gap: Why Drug Discovery’s Data Explosion Hasn’t Solved Its Billion-Dollar Decision Problem
Laurence Arnold, PhD Head of R&D Pelago Bioscience We’ve never had more data in drug discovery. Yet despite this explosion…
Posted inGenetics
Novel Therapeutic Modalities Target the Undruggable
From small molecules and protein therapeutics to gene therapies, biotech industry players have placed their bets on a wide range…
Posted inGenetics
Mass Spectrometry’s Discovery Revolution
Mass spectrometry (MS) has quietly undergone one of the most consequential evolutions in modern drug discovery. Once viewed primarily as…